Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
335.97
+4.68 (+1.41%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
43
44
Next >
Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly
December 01, 2022
The battle for the best weight-loss shot is on with Amgen making a push.
Via
Investor's Business Daily
Analyst Forecasts $101-117/Share Offer Price For Horizon Therapeutics' Buyout
November 30, 2022
Via
Benzinga
Why Horizon Therapeutics Stock Is Skyrocketing Today
November 30, 2022
Three big drugmakers could be interested in acquiring Horizon.
Via
The Motley Fool
Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?
November 30, 2022
Horizon Therapeutics (HZNP) stock is rising higher on Wednesday following reports that the company is considering a buyout.
Via
InvestorPlace
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
November 30, 2022
Reuters
Via
Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $500 Today
November 22, 2022
Via
Benzinga
Credit Suisse Sets Bearish Tone For Amgen; Says Current Setup Not Ideal For Growth
November 18, 2022
Via
Benzinga
What 7 Analyst Ratings Have To Say About Amgen
November 18, 2022
Via
Benzinga
Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies
November 30, 2022
Via
Benzinga
Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi
November 29, 2022
The three companies have until Jan. 10 to decide whether they want to buy Horizon.
Via
Investor's Business Daily
Mild Fed Meeting Minutes Boost Stocks Ahead of Holiday
November 23, 2022
Stocks took home another win on Wednesday, as investors gear up for tomorrow's market closure due to the Thanksgiving holiday.
Via
Talk Markets
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
November 23, 2022
There are reportedly numerous companies in the mix and they're all awaiting data next month.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
November 22, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Analyst Ratings for Amgen
November 18, 2022
Via
Benzinga
Where Amgen Stands With Analysts
November 18, 2022
Via
Benzinga
Amgen Earnings Perspective: Return On Invested Capital
November 17, 2022
Via
Benzinga
2 Ultra-Safe Passive Income Stocks to Buy Right Now
November 10, 2022
These two top biopharma stocks are crushing the 2022 bear market.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022
November 18, 2022
Upgrades
Via
Benzinga
2 Stocks to Buy Whether or Not a Recession Is Coming
November 18, 2022
Both have outperformed the stock market this year.
Via
The Motley Fool
7 Top-Tier Dividend Stocks to Buy for 2023
November 18, 2022
You can find great top-tier dividend stocks in a variety of sectors. These are some of the best names you can buy heading into 2023.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
November 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
How Is The Market Feeling About Amgen?
November 15, 2022
Amgen's (NASDAQ:AMGN) short percent of float has fallen 29.84% since its last report. The company recently reported that it has 11.77 million shares sold short, which is 2.21% of all regular shares...
Via
Benzinga
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
November 15, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?
November 14, 2022
Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report In the medical community, the popularity of regenerative medicine is reportedly soaring primarily...
Via
Benzinga
This US Representative Just Bought Shares Of Airbnb And These 2 Dividend-Paying Stocks
November 12, 2022
Congressman Josh Gottheimer (D-NJ) has made over 1,200 trades in the past three years, with his top two traded stocks being Microsoft (NASDAQ: MSFT) and Apple (NASDAQ: AAPL), reported b
Via
Benzinga
Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review
November 11, 2022
Bitcoin hit a two-year low while Meta and Tesla were in focus.
Via
Investor's Business Daily
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Market Briefing For Wednesday, Nov. 9
November 09, 2022
For the moment, S&P should attempt yet-another trust, react to the CPI just a day later and then possibly go on the defensive, but not for a catastrophe.
Via
Talk Markets
Dow Logs Highest Close Since Late August
November 08, 2022
The Dow stayed hot today, nabbing its third-straight win on the back of a 333-point gain.
Via
Talk Markets
How Amgen Is Closing In On Rivals Novo Nordisk, Eli Lilly With Obesity Drug
November 08, 2022
Early-stage results look promising for Amgen's experimental obesity treatment.
Via
Investor's Business Daily
< Previous
1
2
...
22
23
24
25
26
27
28
29
30
...
43
44
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.